Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US6210671: Humanized antibodies reactive with L-selectin

Share

Filing Information

Inventor(s) Man Sung Co ·
Assignee(s) Protein Design Labs, Inc. ·
Attorney/Agent(s) Townsend & Townsend & Crew ·
Primary Examiner Phillip Gambel ·
Application Number US8579378
Filing date 12/27/1995
Issue date 04/03/2001
Predicted expiration date 12/01/2012
U.S. Classifications 424/154.1  · 435/343.2  · 424/141.1  · 424/143.1  · 424/144.1  · 424/153.1  · 424/173.1  · 435/326  · 435/328  · 435/332  · 435/343  · 435/343.1  · 424/133.1  · 530/387.1  · 530/387.3  · 530/388.1  · 530/388.2  · 530/388.22  · 530/388.7  · 530/388.73  · 530/388.75  · 536/231  · 536/235  · 536/235.3  · 424/130.1  ·
International Classifications --
Kind CodeB1
International Classifications 4241301 · 4241321 · 4241331 · 4241411 · 4241431 · 4241441 · 4241531 · 4241541 · 4241731 · 435 696 · 4351723 · 4352523 · 4353201 · 435 7021 · 435452 · 435326 · 435328 · 435332 · 435334 · 435343 · 4353431 · 4353432 · 435346 · 536 234 · 536 235 · 536 2353 · 5303871 · 5303873 · 5303881 · 53038822 · 5303887 · 53038873 · 53038875 · 5303882 ·
Related U.S. Application DataREFERENCE TO RELATED INVENTIONS
This application is a continuation-in-part of U.S. Ser. No. 08/160,074, filed Nov. 30, 1993 now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/983,946, filed Dec. 1, 1992 now abandoned. This application also derives priority from EP 95 112 895.8, filed Aug. 17, 1995, and EP 95 114 696.8, filed Sep. 19, 1995. All of the prior U.S. and foreign applications from which priority is derived are incorporated by reference in their entirety for all purposes.
Foreign Priority EP95112895 - 08/17/1995 · EP95114696 - 09/19/1995 ·
17 Claims, 13 Drawings


Abstract

Humanized immunoglobulins specifically reactive with L-selectin are prepared employing recombinant DNA technology for use in e.g., treatment of inflammatory disorders.

Independent Claims | See all claims (17)

  1. 1. A humanized immunoglobulin having complementarity determining regions (CDRs) corresponding to CDRs from the mouse DREG-55 donor immunoglobulin and heavy and light chain variable region frameworks corresponding to human acceptor immunoglobulin heavy and light chain frameworks from the Gal antibody, provided that at least one position selected from the group consisting of L50, L62 and L74 is occupied by the amino acid present in the equivalent position of the mouse DREG-55 immunoglobulin light chain variable region framework, which humanized immunoglobulin specifically binds to human L-selectin with an affinity constant between 107 M−1 and five-fold the affinity of the mouse DREG-55 antibody, wherein the mouse DREG-55 antibody has light and heavy chain variable regions designated SEQ. ID. Nos. 14 and 16 respectively.
  2. 10. A humanized immunoglobulin, wherein the amino acid sequence of the mature light chain variable region is shown in the lower lines of FIG. 2A (SEQ. ID. No. 6) and the amino acid sequence of the mature heavy chain variable region is shown in the lower lines of FIG. 2B (SEQ. ID. No. 8).
  3. 11. A humanized immunoglobulin, wherein the amino acid sequence of the mature light chain variable region is shown in the lower lines of FIG. 7A (SEQ. ID. No. 18) and the amino acid sequence of the mature heavy chain variable region is shown in the lower lines of FIG. 7B SEQ. ID, No. 20).
  4. 13. A humanized immunoglobulin having complementarity determining regions (CDRs) corresponding to CDRs from the mouse DREG-200 donor immunoglobulin and heavy and light chain variable region frameworks corresponding to a human acceptor immunoglobulin heavy and light chain frameworks from the Eu antibody, provided that at least one position selected from the group consisting of L87, L54, L66, L76 and at least one position selected from the group consisting of H93, H95, H98, H111, H112, H115, H30, H98, H111, H27, H30, H48 and H72, is occupied by the amino acid present in the equivalent position of the mouse DREG-200 immunoglobulin light or heavy chain variable region framework, which humanized immunoglobulin specifically binds to human L-selectin with an affinity constant between 107 M−1 and three-fold the affinity of the mouse DREG-200 antibody, wherein the mouse DREG-200 antibody has light and heavy chain variable regions designated SEQ. ID. Nos. 2 and 4 respectively.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5316913* Stanford University Butcher et al. May 1994
US5530101* Protein Design Labs, Inc. Queen et al. Jun 1996
US5679346* Dana-Farber Cancer Institute Tedder et al. Oct 1997

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0440351*MERCK & CO. INC.Jan 1991
* cited by examiner

Other Publications

Edgington Biotechnology 10: 383-389 (1992).*
Ward et al. Therapeutic Immunology : 1: 165-171 (1994).*
Waldmann Science 252: 1657-1662 (1981).*
Kishimoto Blood 78: 805-811 (1991).*
Kishimoto PNAS 87: 2244-2248 (1990).*
Von Anorian et al. PNAS 88: 7538-7542 (1991).*
Carlos Immunol. Rev. 114: 5-28 (1990).*
Kahan Cur. Opin Immunol. 4: 553-560 (1992).*
Albelda et al. FASEB Journal 8: 504-512 (1994).*
Welply et al. Biochimia et Biophysica Acta 1197: 215-226 (1994).*
Paul (Ed) Fundamental Immunology Raven Press 1993 p. 242 only.*
* cited by examiner

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
AU2003260335 COLLEN RES FOUNDATION VZW D GILLES JEAN-GUY G et al. Feb 2004
EP1975231 CORIXA CORPORATION Alexander Gaiger et al. Aug 2011
US7462698 Y's Therapeutics Co., Ltd. Teikichi Aoyagi et al. Dec 2008
US7449616 Pfizer Inc. Jaume Pons et al. Nov 2008
US7575880 Elan Pharma International Limited Dale B. Schenk et al. Aug 2009
US7179892 Neuralab Limited Guriq Basi et al. Feb 2007
US7425329 Rinat Neuroscience Corp. David L. Shelton et al. Sep 2008
US7588766 Elan Pharma International Limited Dale B. Schenk Sep 2009
US7569672 Raven biotechnologies, inc. Jennie P. Mather et al. Aug 2009
US7255860 Rinat Neuroscience Corp. David L. Shelton et al. Aug 2007
US7252822 Rinat Neuroscience Corp. David L. Shelton et al. Aug 2007
US7625560 Janssen Alzheimer Immunotherapy Guriq Basi et al. Dec 2009
US7569364 Pfizer Inc. Arnon Rosenthal et al. Aug 2009
US7582733 Elan Pharma International Limited Guriq Basi et al. Sep 2009
US7862812 Lpath, Inc. Roger A. Sabbadini Jan 2011
US7906120 Abbott Laboratories Mario Mezler et al. Mar 2011
US7893214 Janssen Alzheimer Immunotherapy Dale B. Schenk Feb 2011
US7655232 Pfizer Inc. Jaume Pons et al. Feb 2010
US7655231 Pfizer Inc. David L. Shelton et al. Feb 2010
US7700751 Janssen Alzheimer Immunotherapy Guriq Basi et al. Apr 2010
US7744878 Raven biotechnologies, inc. Jennie P. Mather Jun 2010
US7763250 Rinat Neuroscience Corp. Arnon Rosenthal et al. Jul 2010
US7790856 Janssen Alzheimer Immunotherapy Dale B. Schenk Sep 2010
US7794713 Lpath, Inc. Roger A. Sabbadini et al. Sep 2010
US7807165 Rinat Neuroscience Corp. Arnon Rosenthal et al. Oct 2010
US7148038 Raven biotechnologies, inc. Jennie P. Mather Dec 2006
US7256273 Elan Pharma International Limited Guriq Basi et al. Aug 2007
US7927594 Rinat Neuroscience Corp. Arnon Rosenthal et al. Apr 2011
US7964192 Janssen Alzheimer Immunotherapy Dale B. Schenk Jun 2011
US8007800 Pfizer Inc. David L. Shelton et al. Aug 2011
US8003097 Janssen Alzheimer Immunotherapy Sally Schroeter et al. Aug 2011
US8030469 SBI Incubation Co., Ltd. Teikichi Aoyagi et al. Oct 2011
US8034339 Janssen Alzheimer Immunotherapy Dale B. Schenk Oct 2011
US8034348 Janssen Alzheimer Immunotherapy Dale B. Schenk et al. Oct 2011
US8034346 Rinat Neuroscience Corp. David L. Shelton et al. Oct 2011
US8097425 Tethys Bioscience, Inc. Michael S. Urdea et al. Jan 2012
US8088384 Rinat Neuroscience Corp. Jaume Pons et al. Jan 2012
US8128928 Wyeth LLC Guriq Basi et al. Mar 2012
US8158124 Lpath, Inc. Roger A. Sabbadini et al. Apr 2012
US8183357 MacroGenics, Inc. Jennie P. Mather et al. May 2012

Patent Family

The current document is not in a family.